Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00890968 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Triamcinolone Acetonide DuraPeel to Treat Hand Dermatitis
A Phase 2 study, sponsored by ZARS Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT00890968 is a Phase 2 study that has completed, run by ZARS Pharma. The registered enrollment target is 56 participants.
The verdict
NCT00890968, a Phase 2 study, has completed, sponsored by ZARS Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Triamcinolone Acetonide (TAC) DuraPeel is safe and effective in the treatment of hand dermatitis.
Interventions
- DRUG Triamcinolone Acetonide (TAC) DuraPeel
- DRUG Placebo DuraPeel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00890968
The ClinicalTrials.gov registry entry for NCT00890968 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ZARS Pharma, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Triamcinolone Acetonide (TAC) DuraPeel is the first listed.
NCT00890968 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00890968 about?
NCT00890968 is a clinical study titled "Safety and Efficacy Study of Triamcinolone Acetonide DuraPeel to Treat Hand Dermatitis". The purpose of this study is to determine whether Triamcinolone Acetonide (TAC) DuraPeel is safe and effective in the treatment of hand dermatitis.
What is the current status of trial NCT00890968?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2009-04. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00890968?
The interventions under investigation include: Triamcinolone Acetonide (TAC) DuraPeel (DRUG), Placebo DuraPeel (DRUG).
Who is sponsoring clinical trial NCT00890968?
This trial is sponsored by ZARS Pharma, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.